Kaposi's sarcoma staging: Difference between revisions
No edit summary |
No edit summary |
||
Line 19: | Line 19: | ||
Tumor (T) | Tumor (T) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Confined to skin and lymph | * Confined to [[skin]] and [[lymph node]]s | ||
* Minimal oral lesions (non-nodular kaposi's sarcoma confined to the palate) | * Minimal [[oral]] lesions (non-nodular kaposi's sarcoma confined to the [[palate]]) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Tumor-associated edema or ulceration | * Tumor-associated [[edema]] or [[ulceration]] | ||
* Extensive oral lesions present | * Extensive oral lesions present | ||
* Gastrointestinal lesions present | * [[Gastrointestinal]] lesions present | ||
* Kaposi sarcoma present in other non-nodal viscera | * Kaposi sarcoma present in other non-nodal [[viscera]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" align=center | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" align=center | | ||
Immune system (I) | Immune system (I) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* CD4 cell count ≥ 200/mL | * CD4 [[T cell]] count ≥ 200/mL | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* CD4 cell count < 200/mL | * CD4 [[T cell]] count < 200/mL | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" align=center | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" align=center | | ||
Systemic illness (S) | Systemic illness (S) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* No history of opportunistic infection or thrush | * No previous history of opportunistic infection or thrush | ||
* | * [[B symptoms]] are not present | ||
* Karnofsky performance status score ≥ 70 | * Karnofsky performance status score ≥ 70 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Positive history of opportunistic infection or thrush | * Positive history of [[opportunistic infection]]s or [[oral thrush]] | ||
* | * [[B symptoms]] are present | ||
* Karnofsky performance status score < 70 | * Karnofsky performance status score < 70 | ||
|} | |} |
Revision as of 16:09, 20 January 2016
Kaposi's sarcoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Kaposi's sarcoma staging On the Web |
American Roentgen Ray Society Images of Kaposi's sarcoma staging |
Risk calculators and risk factors for Kaposi's sarcoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
There is no established system for the staging of Kaposi's sarcoma among immune competent patients. However, the staging of AIDS-associated Kaposi's sarcoma is based on the AIDS Clinical Trials Group (ACTG) staging system. According to the ACTG staging system, there are 2 groups of AIDS-associated Kaposi's sarcoma based on the tumor size, immune status, and the presence of any systemic illness.[1][2][3][4][5]
Staging
- There is no established system for the staging of Kaposi's sarcoma among immune competent patients.
- The staging of AIDS-associated Kaposi's sarcoma is based on the AIDS Clinical Trials Group (ACTG) staging system. According to the ACTG staging system, there are 2 groups of AIDS-associated Kaposi's sarcoma based on the tumor size, immune status, and the presence of any systemic illness.
Factors | Good Risk (Subscript 0) | Poor Risk (Subscript 1) |
---|---|---|
Tumor (T) |
|
|
Immune system (I) |
|
|
Systemic illness (S) |
|
|
- Good risk groups include T0S0, T1S0, or T0S1
- Poor risk groups include T0S0I1, T1S0I1, T0S1I1, T1S1, or T1S1I1
References
- ↑ Kaposi Sarcoma Treatment–for health professionals. National Cancer Institute (2015) http://www.cancer.gov/types/soft-tissue-sarcoma/hp/kaposi-treatment-pdq#section/_15 Accessed on January, 20 2015
- ↑ Krown SE, Metroka C, Wernz JC (1989). "Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee". J Clin Oncol. 7 (9): 1201–7. PMID 2671281.
- ↑ Krown SE, Testa MA, Huang J (1997). "AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee". J Clin Oncol. 15 (9): 3085–92. PMID 9294471.
- ↑ Sarcoma- Kaposi Guide. Cancer.Net (2015) http://www.cancer.net/cancer-types/sarcoma-kaposi/risk-factors-and-prevention Accessed on January, 20 2015
- ↑ How is Kaposi sarcoma staged? American Cancer Association (2015) http://www.cancer.org/cancer/kaposisarcoma/detailedguide/kaposi-sarcoma-staging Accessed on January, 20 2016